Harnessing dual-channel probiotics to synergistically correct intestinal and vaginal dysbiosis after antibiotic disruption.

Authors

Xuanqi Zhao, Qifa Huang, Yujuan Liu, Xia He, Weijun Chen, Yan Liu, Lihong Gan, Jing Wei, Hongyan Zhang, Tingtao Chen

Published in

NPJ biofilms and microbiomes. Volume 11. Issue 1. Pages 174. Aug 25, 2025. Epub Aug 25, 2025.

Abstract

Antibiotics are widely used to treat infectious diseases, yet antibiotic therapy has been shown to disrupt symbiotic microbiota. Notably, the dosage and duration of antibiotic use for specific infections may exert detrimental effects on microbiota in non-infected sites. Here, we propose a dual-channel probiotic delivery strategy to address gut and vaginal dysbiosis caused by antibiotic therapies. In a Helicobacter pylori infection model, oral administration of Limosilactobacillus reuteri NCU-15 alleviated gastritis and protected the intestinal barrier and microbiota. In a vaginal dysbiosis model, intravaginal delivery of Lactobacillus crispatus NCU-23 reduced local inflammation and apoptosis, restoring vaginal microbial homeostasis. In the entero-vaginal disordered mice, dual-channel probiotic therapy produced synergistic effects by reducing inflammation, inhibiting apoptosis, and reestablishing microbial balance. These findings demonstrate the potential of dual-channel probiotic intervention to modulate gut-vaginal microbiota interactions and offer a scientific basis for developing strategies to prevent or treat antibiotic-induced dysbiosis.

PMID:
40855059
Bibliographic data and abstract were imported from PubMed on 26 Aug 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.